Urogen Pharma (NASDAQ:URGN) Raised to Hold at Wall Street Zen

Urogen Pharma (NASDAQ:URGN) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other research firms have also recently weighed in on URGN. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the stock a “buy” rating in a report on Friday, June 13th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Urogen Pharma in a report on Tuesday, August 5th. The Goldman Sachs Group set a $16.00 target price on shares of Urogen Pharma and gave the company a “neutral” rating in a report on Friday, June 13th. Scotiabank reaffirmed an “outperform” rating on shares of Urogen Pharma in a report on Friday, June 13th. Finally, Piper Sandler began coverage on shares of Urogen Pharma in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $32.00.

Urogen Pharma Trading Down 2.4%

URGN stock opened at $18.79 on Friday. Urogen Pharma has a twelve month low of $3.42 and a twelve month high of $21.71. The company’s 50 day moving average is $18.19 and its two-hundred day moving average is $12.85. The stock has a market cap of $869.23 million, a P/E ratio of -5.66 and a beta of 1.10.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The company had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. On average, equities research analysts predict that Urogen Pharma will post -3.12 earnings per share for the current year.

Insider Activity

In related news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $17.69, for a total value of $176,900.00. Following the sale, the insider directly owned 148,229 shares in the company, valued at $2,622,171.01. The trade was a 6.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jason Drew Smith sold 1,520 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the sale, the general counsel owned 43,305 shares in the company, valued at $827,558.55. This represents a 3.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,062 shares of company stock worth $465,115 over the last quarter. Insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Osaic Holdings Inc. boosted its position in shares of Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after buying an additional 3,070 shares in the last quarter. CWM LLC raised its stake in Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock valued at $58,000 after purchasing an additional 5,140 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Urogen Pharma in the 4th quarter valued at about $67,000. GAMMA Investing LLC raised its stake in Urogen Pharma by 6,908.4% in the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after purchasing an additional 7,392 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after purchasing an additional 5,571 shares during the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.